Proposed Legislation Would Create a New Conditional Approval Pathway to Market for Regenerative Medicine Products

In the emerging world of regenerative medicine, there is a stark dichotomy in the level of regulation applied to products derived from human cells and tissues, or what FDA calls “human cells, tissue or cellular and tissue-based products” (HCT/Ps).